LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE

Pre-Launch

lamivudine; tenofovir disoproxil fumarate; nevirapine

Hetero

NDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

0/8 — Limited

Drug data last refreshed 2w ago · AI intelligence enriched 2w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

This is a fixed-dose combination tablet containing lamivudine, tenofovir disoproxil fumarate, and nevirapine—three nucleoside/nucleotide reverse transcriptase inhibitors and a non-nucleoside reverse transcriptase inhibitor used for HIV-1 treatment. The combination works by blocking reverse transcriptase enzymes needed for viral replication. This product is positioned as an oral, once-daily or twice-daily antiretroviral therapy for treatment-naïve or treatment-experienced HIV patients.

Pre-Launch

Pre-launch stage indicates early-stage team building; commercial infrastructure and launch readiness initiatives are likely underway with smaller, focused teams.

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Career Relevance

This pre-launch product represents an early-stage career opportunity with Hetero in a mature therapeutic area. Roles are currently limited but will expand significantly upon regulatory approval, with emphasis on launch strategy, market penetration in emerging markets, and competitive positioning against established combination therapies.

Brand ManagerField Sales Representative

Worked on LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.